News | July 08, 2022
WuXi STA opens Oligonucleotide and Peptide manufacturing facility
Site Enhances New Modality CRDMO Platform Capacity for Customers
Site Enhances New Modality CRDMO Platform Capacity for Customers
Under the terms of the agreement, Bachem will provide the appropriate engineering infrastructure and expertise to implement Lilly’s novel oligonucleotide manufacturing technology
EUROAPI listing on Euronext Paris will occur in H1 2022, despite volatile market conditions
The company is focused on the development of novel treatments for RNA viruses
Transformational partnership establishes PCI as a CDMO and broadens capabilities across drug product lifecycle
Alnylam is the latest partner in the Medicines Manufacturing Innovation Centre’s third Grand Challenge project, which aims to revolutionise the manufacturing process for oligonucleotide therapies
The investment programme is expected to significantly reduce commercialisation lead times, costs and introduce more sustainable manufacturing processes
Subscribe To Our Newsletter & Stay Updated
